methyl 3-[(4-bromophenyl)oxy]-5-[(1-methylethyl)oxy]benzoate | 863454-75-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-[(4-bromophenyl)oxy]-5-[(1-methylethyl)oxy]benzoate
• 英文别名: 3-(4-bromo-phenoxy)-5-isopropoxy-benzoic acid methyl ester；Methyl 3-(4-bromophenoxy)-5-isopropoxybenzoate；methyl 3-(4-bromophenoxy)-5-propan-2-yloxybenzoate
• CAS: 863454-75-5
• 化学式: C₁₇H₁₇BrO₄
• 分子量: 365.224
• InChiKey: RUGYVURJCPCMQV-UHFFFAOYSA-N

物化性质

• 沸点：
  434.9±35.0 °C(Predicted)
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-[(4-bromophenyl)oxy]-5-[(1-methylethyl)oxy]benzoate 、 亚磷酸二异丙酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 三乙基硅烷 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 以65%的产率得到3-[4-(diisopropoxy-phosphoryl)-phenoxy]-5-isopropoxy-benzoic acid methyl ester
  参考文献：
  名称：

  [EN] NOVEL ACTIVATORS OF GLUCOKINASE
  [FR] NOUVEAUX ACTIVATEURS DE GLUCOKINASE

  摘要：

  公开号：

  WO2009023718A3
• 作为产物：
  描述：

  methyl 3-(4-aminophenoxy)-5-isopropoxybenzoate 在 亚硝酸特丁酯 、 copper(ll) bromide 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 1.17h， 以71%的产率得到methyl 3-[(4-bromophenyl)oxy]-5-[(1-methylethyl)oxy]benzoate
  参考文献：
  名称：

  [EN] NOVEL ACTIVATORS OF GLUCOKINASE
  [FR] NOUVEAUX ACTIVATEURS DE GLUCOKINASE

  摘要：

  公开号：

  WO2009023718A3

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2005080360A1

  公开（公告）日：2005-09-01

  Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from -C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C) alkyl and HET-2; R5 is hydrogen or (1-4C) alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them and processes for their preparation are also described.

  分子式为（I）的化合物，其中：R1为甲基；R2选自-C（O）NR4R5，SO2NR4R5，S（O）pR4和HET-2；HET-1是一个5或6元环的、可选地取代的C-连接的杂芳基环；HET-2是一个4、5或6元环的、C-或N-连接的、可选地取代的杂环基环；R3选自卤素、氟甲基、二氟甲基、三氟甲基、甲基、甲氧基和氰基；R4选自氢、可选地取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或者R4和R5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系统；HET-3例如是一个可选地取代的N-连接的、4、5或6元环的、饱和或部分不饱和的杂环基环；p是（在每次出现时）独立地为0、1或2；m为0或1；n为0、1或2；但当m为0时，则n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK活化剂的用途、含有它们的制药组合物以及它们的制备方法。
• Compounds
  申请人：Johnstone Craig

  公开号：US20080312207A1

  公开（公告）日：2008-12-18

  Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from —C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C) alkyl and HET-2; R5 is hydrogen or (1-4C) alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them and processes for their preparation are also described.

  化合物的公式（I），其中：R1为甲基；R2选自-C（O）NR4R5，SO2NR4R5，S（O）pR4和HET-2; HET-1是一个5或6成员的，可选取代的C-连接的杂芳基环；HET-2是一个4、5或6成员的，C-或N-连接的可选取代的杂环基环；R3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基；R4选自例如氢，可选取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或R4和R5与它们连接的氮原子一起可以形成由HET-3定义的杂环基环系统；HET-3例如是一个可选取代的N-连接的，4、5或6成员的，饱和或部分不饱和的杂环基环；p为（每次独立地）0、1或2；m为0或1；n为0、1或2；前提是当m为0时，n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK激活剂的用途，含有它们的制药组合物以及它们的制备方法。
• NOVEL ACTIVATORS OF GLUCOKINASE
  申请人：Tian Feng

  公开号：US20110294758A1

  公开（公告）日：2011-12-01

  The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了I和II式的新型化合物，以及其药学上可接受的盐和共晶体，具有葡萄糖激酶激活剂活性。本发明还提供了包括该化合物的制药组合物，以及治疗、预防、延迟发病时间或减少一种或多种葡萄糖激酶激活剂所指示的疾病或症状发展或进展的方法，包括1型和2型糖尿病、糖耐量受损、胰岛素抵抗和高血糖。本发明还提供了制备I和II式化合物（包括其盐和共晶体）以及包括该化合物的制药组合物的方法。
• Activators of glucokinase
  申请人：Tian Feng

  公开号：US08940927B2

  公开（公告）日：2015-01-27

  The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了具有葡萄糖激酶激活剂活性的I和II式新化合物及其药学上可接受的盐和共晶体。本发明还提供了包含相同化合物的制药组合物以及治疗、预防、延缓发病时间或减少一种或多种葡萄糖激酶激活剂所指示的疾病或情况的方法，包括1型和2型糖尿病、糖耐量受损、胰岛素抵抗和高血糖。本发明还提供了制备I和II式化合物，包括其盐和共晶体的过程，以及包含相同化合物的制药组合物。
• COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1718625A1

  公开（公告）日：2006-11-08